Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting.
PHILADELPHIA, Nov. 7 /PRNewswire/ -- Data from an investigational, open-label, randomized study assessing extended dosing regimens of PROCRIT(R) (Epoetin alfa) in treating anemia in subjects with Stages 3 - 4 chronic kidney disease (CKD) were presented today at the American Society of Nephrology 41st Annual Meeting. All...

Affymax Advances in Clinical Trials of Hematide to Treat Anemia in Chronic Renal Failure Patients.
HEALTH AND BEAUTY CLOSE-UP-7 November 2008-Affymax Advances in Clinical Trials of Hematide to Treat Anemia in Chronic Renal Failure Patients(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com Affymax announced that enrollment has been completed in the second of four Phase 3 clinical trials of its lead investigational therapy, Hematide, which...

Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST.
NEW YORK, Nov. 7 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. will hold a conference call on Tuesday, November 11, 2008 at 8:30 a.m. EST to discuss the third quarter 2008 financial results. Michael S. Weiss, Chairman and Chief Executive Officer of the Company, will host the call. Keryx will announce...

Media Alert From Residual Risk Reduction Initiative (R3i): 19:00 CST Sunday 9 November 2008.
NEW ORLEANS, Louisiana, November 7 /PRNewswire/ -- - Residual Vascular Risk Reduction: The Global Call to Action - Announcement of the Launch of the Residual Risk Reduction Initiative: R3i KEY FACTS: Residual Risk Reduction Initiative (R3i) calls for action to reduce the lipid...

Acologix AC-200 Demonstrates Positive Effect on Bone in Preclinical Model of Chronic Kidney Disease.
Data Presented at the 41st Annual Meeting of the American Society of Nephrology HAYWARD, Calif., Nov. 7 /PRNewswire-FirstCall/ -- Acologix, Inc., a privately held biopharmaceutical company, will present data indicating that its therapeutic product candidate AC-200 improved bone architecture in a rat model of chronic kidney disease....

Dendreon Reports Third Quarter 2008 Financial Results.
SEATTLE, Nov. 7 /PRNewswire-FirstCall/ -- Dendreon Corporation today reported results for the quarter ended September 30, 2008. Revenue for the third quarter of 2008 was $26,000 compared to $112,000 for the quarter ended September 30, 2007. Revenue for the nine months ended September 30, 2008 was $83,000 compared to...

Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update.
- Conference Call Today at 4:30 p.m. Eastern Time - SAN FRANCISCO, Nov. 10 /PRNewswire-FirstCall/ -- Medivation, Inc. today reported on its corporate progress and financial results for the quarter ended September 30, 2008. "The third quarter represented another quarter of significant achievement and progress...

Endocare and Galil Medical Sign Definitive Merger Agreement.
Combined Company to Expand Cryoablation Clinical Programs and Broaden Global Business Presence; Also Signs Agreement for $16.25 Million Financing with Current Institutional Investors IRVINE, Calif. and YOKNEAM, Israel, Nov. 10 /PRNewswire-FirstCall/ -- Endocare, Inc. and privately held Galil Medical, Ltd., both innovative medical device companies, today announced...

Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results.
Keryx to Host Investor Conference Call on Tuesday, November 11, 2008 at 8:30am EST NEW YORK, Nov. 10 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. , a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including...

Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units.
SAN DIEGO, Nov. 10 /PRNewswire-FirstCall/ -- Cardium Therapeutics today reported financial results and highlights for its third quarter ended September 30, 2008, and outlined revised business strategies for its three operating units: (1) InnerCool Therapies, (2) Tissue Repair Company, and (3) Cardium Biologics. (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO) InnerCool Therapies,...